University Hospital Sart Tilman, Department of Dermatopathology, Liège, Belgium.
Expert Opin Biol Ther. 2010 Aug;10(8):1197-208. doi: 10.1517/14712598.2010.500283.
Alopecia, psoriatic arthritis, the metabolic syndrome, inflammatory bowel diseases and cardiovascular diseases may occur as skin psoriatic comorbidities. TNF-alpha antagonists are used to treat psoriasis. Adalimumab is one of the recognized active agents for this indication.
The current peer-reviewed publications and presentation of original findings.
Adalimumab is active on recalcitrant psoriasis and some of its comorbidities, particularly arthropathies and Crohn's disease. However, the progression of the radiological alterations is limited with regression of the bony erosions. Psoriatic enthesopathy also regresses. Mortality associated with psoriasis arthropathy is on the decline. Crohn's disease, the most frequent inflammatory bowel comorbidity of psoriasis, is responsive to adalimumab. The effect of adalimumab on the metabolic syndrome and cardiovascular involvement is more erratic. The spectacular effects of adalimumab may be associated with some adverse effects. In particular, despite a marked reduction in the psoriasis area-and-severity index (PASI) score some new acute lesions of cutaneous psoriasis may develop corresponding to paradoxical psoriasis. Other potential adverse effects include infections, granulomas, rapid growth of cancers and occurrence of lymphomas.
Adalimumab frequently controls moderate-to-severe forms of cutaneous psoriasis and some of its comorbidities.
脱发、银屑病关节炎、代谢综合征、炎症性肠病和心血管疾病可能发生作为皮肤银屑病的合并症。肿瘤坏死因子-α拮抗剂用于治疗银屑病。阿达木单抗是这一适应症的公认的有效药物之一。
目前的同行评议的出版物和原始发现的介绍。
阿达木单抗对顽固的银屑病及其一些合并症是有效的，特别是关节炎和克罗恩病。然而，放射学改变的进展是有限的，骨质侵蚀得到了缓解。银屑病肌腱病也会消退。与银屑病关节炎相关的死亡率正在下降。克罗恩病是银屑病最常见的炎症性肠病合并症，对阿达木单抗有反应。阿达木单抗对代谢综合征和心血管疾病的影响则更加不稳定。阿达木单抗的显著疗效可能与一些不良反应有关。特别是，尽管银屑病面积和严重程度指数（PASI）评分有明显下降，但可能会出现新的急性皮肤银屑病病变，对应于矛盾性银屑病。其他潜在的不良反应包括感染、肉芽肿、癌症的快速生长和淋巴瘤的发生。
阿达木单抗经常控制中度至重度的皮肤银屑病及其一些合并症。
